People with more body shame, weight worries, and anti-fat bias will tolerate medication side effects more readily
Step 1: Comprehensive Online Medical Questionnaire The evaluation begins with detailed digital assessment collecting extensive health information: Medical History Documentation: Complete inventory of past and current health conditions including cardiovascular disease (heart attack, stroke, heart failure), kidney function impairment or chronic kidney disease, gastrointestinal disorders (Crohn's disease, ulcerative colitis, gastroparesis), thyroid problems (hypothyroidism, hyperthyroidism, thyroid nodules), pancreatitis history or recurrent episodes, gallbladder disease or previous cholecystectomy, mental health conditions (depression, anxiety, eating disorders), and any previous experiences with weight loss medications including outcomes and side effects encountered
Every commitment length
The medication's effects on your central nervous system also matter
In September 2022, Eli Lilly published the results of its preclinical studies on LY3437943 in the journal Cell Metabolism, in an article titled "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept." In vitro and in vivo validation of the triple agonist effect of LY3437943: Eli Lilly's research results show that LY3437943 demonstrates superior weight loss effects compared to GLP-1 receptor (GLP-1R) selective agonists (GLP-1 RA), GLP-1R and GCGR dual agonists (Cotadutide or 05677), and GLP-1R and GIPR dual agonists
doi: 10.1016/j.regpep.2011.05.006 170 TrokeRCTanTMBloomSR
